Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer

Cancer Research

Volumn 77, Issue 9, 2017, Pages 2213-2221

  Cejalvo, Juan M ^a,b   De Dueñas, Eduardo Martínez ^c,d   Galván, Patricia ^e   García Recio, Susana ^a   Gasión, Octavio Burgués ^d,f   Paré, Laia ^a   Antolín, Silvia ^d,g   Martinello, Rosella ^a   Blancas, Isabel ^d,h   Adamo, Barbara ^a   Guerrero Zotano, Ángel ^d,i   Muñoz, Montserrat ^a   Nucíforo, Paolo ^e   Vidal, María ^a   Pérez, Ramon M ^d,j   López Muniz, José I Chacón ^d,k   Caballero, Rosalía ^d   Peg, Vicente ^l   Carrasco, Eva ^d   Rojo, Federico ^d,m,t   Perou, Charles M ⁿ   Cortés, Javier ^d,o   Adamo, Vincenzo ^p   Albanell, Joan ^d,q,t   Gomis, Roger R ^b,r   Lluch, Ana ^d,s,t   Prat, Aleix ^a,e   more..

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^c HOSPITAL PROVINCIAL DE CASTELLÓN   (Spain)

^d P de la Castellana 181   (Spain)

^e VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^f HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^g HOSPITAL JUAN CANALEJO   (Spain)

^h HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

ⁱ INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^j Hospital Universitario Quiron Madrid   (Spain)

^k HOSPITAL VIRGEN DE LA SALUD   (Spain)

^l HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^m Hospital UniversitarioFundación Jiménez Díaz   (Spain)

ⁿ UNIVERSITY OF NORTH CAROLINA   (United States)

^o HOSPITAL RAMÓN Y CAJAL   (Spain)

^p UNIVERSITY OF MESSINA   (Italy)

^q HOSPITAL DEL MAR   (Spain)

^r INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^s UNIVERSITY OF VALENCIA   (Spain)

^t INSTITUTO DE SALUD CARLOS III   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN; TRANSCRIPTOME; TUMOR MARKER; TUMOR PROTEIN;

ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTATIC BREAST CANCER; OVERALL SURVIVAL; PREDICTION; PRIMARY BREAST CANCER; PRIORITY JOURNAL; ADULT; AGED; BIOSYNTHESIS; BREAST TUMOR; CLASSIFICATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST NEOPLASMS; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTOR, ERBB-2; TRANSCRIPTOME;

EID: 85019027159     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-16-2717     Document Type: Article

References (47)

1. Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, et al. ESO-ESMO 2nd International Consensus Guidelines for advanced breast cancer (ABC2). Ann Oncol 2014;25:1871-88.
2. O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011;364:205-14.
3. Baselga J, Campone M, Piccart M, Burris HA III, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-9.
4. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptorpositive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2015;16:25-35.
5. Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366:109-19.
6. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002;2:563-72.
7. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007;7:834-46.
8. Marlow R, Honeth G, Lombardi S, Cariati M, Hessey S, Pipili A, et al. A novel model of dormancy for bone metastatic breast cancer cells. Cancer Res 2013;73:6886-99.
9. Amir E, Clemons M. Should a biopsy be recommended to confirmmetastatic disease in women with breast cancer? Lancet Oncol 2009;10:933-5.
10. Fabi A,Di Benedetto A, Metro G, Perracchio L, Nisticó C, Di Filippo F, et al. HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. Clin Cancer Res 2011; 17:2055-64.
11. de Dueñas EM, Hernández AL, Zotano AG, Carrión RM, López-Muñiz JI, Novoa SA, et al. Prospective evaluation of the conversion rate in the receptor status between primary breast cancer andmetastasis: results from theGEICAM 2009-03 ConvertHER study. Breast Cancer Res Treat 2014;143:507-15.
12. Schiavon G, Hrebien S, Garcia-Murillas I, Cutts RJ, Pearson A, Tarazon N, et al. Analysis of ESR1 mutation in circulating tumor DNA demostrates evolution during therapy for metastatic breast cancer. Sci Transl Med 2015;7:313ra182.
13. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
14. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011;5:5-23.
15. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010;12:R68.
16. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
17. Millikan R, Newman B, Tse C-K,Moorman PG, Conwy K, Dressler LG, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008;109:123-39.
18. Anderson WF, Rosenberg PS, Prat A, Perou CM, Sherman ME, et al. How many etiological subtypes of breast cancer: two, three, four, or more? J Natl Cancer Inst 2014;106:dju152.
19. Prat A, Parker JS, Fan C, Cheang MC, Miller LD, Bergh J, et al. Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Ann Oncol 2012;23: 2866-73.
20. Prat A, Carey LA, Adamo B, Vidal M, Tabernero J, Cortés J, et al. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. J Natl Cancer Inst 2014;106: dju152.
21. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptorpositive breast cancer. Clin Cancer Res 2010;16:5222-32.
22. Prat A, Bianchini G, Thomas M, Belousov A, Cheang MC, Koehler A, et al. Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study. Clin Cancer Res 2014;20:511-21.
23. Usary J, ZhaoW, Darr D, Roberts PJ, Liu M, Balletta L, et al. Predicting drug responsiveness in human cancers using genetically engineered mice. Clin Cancer Res 2013;19:4889-99.
24. Prat A, Cheang MC, Martin M, Parker JS, Carrasco E, Caballero R, et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol 2013;31:203-9.
25. Cheang M, Martin M, Nielsen T, Prat A, Rodriguez-lescure A, Ruiz A, et al. Quantitative hormone receptors, triple-negative breast cancer (TNBC), and molecular subtypes: a collaborative effort of the BIG-NCI NABCG. J Clin Oncol 2012;30:(suppl; abstr 1008).
26. Prat A, Cheang MC, Galván P, Nucíforo P, Paré L, Adamo B, et al. Prognostic value of intrinsic subtypes in hormone receptor-positive metastatic breast cancer treated with letrozole with or without lapatinib. JAMA Oncol 2016;2:1287-94.
27. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 2008;26:317-25.
28. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. JClin Oncol 2009;27:1160-7.
29. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010;12:R68.
30. Hu Z, Fan C, Livasy C, He X, Oh DS, Ewend MG, et al. A compact VEGF signature associated with distantmetastases and poor outcomes.BMCMed 2009;7:9.
31. Moyano JV, Evans JR, Chen F, Lu M, Werner ME, Yehiely F, et al. aBCrystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest 2006;116:261-70.
32. Sundvall M, Iljin K, Kilpinen S, Sara H, Kallioniemi OP, Elenius K. Role of ErbB4 in breast cancer. JMammary Gland BiolNeoplasia 2008;13:259-68.
33. Weigman VJ, Chao HH, Shabalin AA, He X, Parker JS, Nordgard SH, et al. Basal-like breast cancerDNAcopy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat 2012;133:865-80.
34. Martin M, Brase JC, Ruiz A, Prat A, Kronenwett R, Calvo L, et al. Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study. Breast Cancer Res Treat 2016;156:81-9.
35. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 2009;69:4116-24.
36. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol 2003;4:P3.
37. Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C, et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 2012;30:587-92.
38. Dieci MV, Barbieri E, Piacentini F, Ficarra G, Betelli S, Dominici M, et al. Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-Insitution analysis. Ann Oncol 2013; 24:101-8.
39. Prat A, Ellis MJ, Perou CM. Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol 2011;9:48-57.
40. Harrell JC, Prat A, Parker JS, Fan C, He X, Carey L, et al. Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Res Treat 2012;132:523-35.
41. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010;464:999-1005.
42. Lee JY, Park K, Lee E, Ahn T, Jung HH, Lim SH, et al. Gene expression profiling of breast cancer brain metastasis. Sci Rep 2016;6:28623.
43. Meric-Bernstam F, Frampton GM, Ferrer-Lozano J, Yelensky R, Pérez-Fidalgo JA, Wang Y, et al. Concordance of genomic alterations between primary and recurrent breast cancer. Mol Cancer Ther 2014;13:1382-9.
44. Katoh M, Nakagama H. FGF receptors: cancer biology and therapeutics. Med Res Rev 2014;34:280-300.
45. Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. Clin Cancer Res 2016;22:259-67.
46. EllisMJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausalwomenwith estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. J Clin Oncol 2011;29:2342-9.
47. Dunbier AK, Anderson H, Ghazoui Z, Salter J, Parker JS, Perou CM, et al. Association between breast cancer subtypes and response to neoadjuvant anastrozole. Steroids 2011;76:736-40.